Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (108) clinical trials

The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part

Phase

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with ...

Phase

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

OBJECTIVES: Primary - Determine the maximum-tolerated dose (MTD) and recommended phase II dose of sorafenib in pediatric patients with relapsed or refractory solid tumors. - Determine whether pediatric patients with relapsed or refractory leukemia can tolerate the MTD of sorafenib for solid tumors. - Determine the tolerability, active N-oxide metabolite, ...

Phase

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II Stage III or Stage IV T-Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary - Establish the safety and dose-limiting toxicities of alemtuzumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) chemotherapy in patients with newly diagnosed, stage II-IV aggressive peripheral T-cell non-Hodgkin's lymphoma. - Measure the pharmacokinetics of alemtuzumab using different subcutaneous doses and schedules to determine the dose ...

Phase

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and cisplatin followed by high dose chemotherapy with treosulfan, etoposide and cisplatin (TEC) an autologous peripheral blood stem cell transplantation(aPBSCT). In case of only partial remission a second identical high dose chemotherapy and aPBSCT follows. Patients with primary refractory disease ...

Phase

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Several groups have explored the possible synergistic interactions between proteasome and HDAC inhibitors in malignant hematopoietic cells. Bortezomib and HDACIs synergistically induce apoptosis, mitochondrial injury (via BAX), ROS generation and oxidative injury in human leukemia and myeloma cells. In view of this evidence, we are proposing a trial to examine ...

Phase

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

PRIMARY OBJECTIVES: I. To determine the safety and potential efficacy of reduced intensity conditioning with fludarabine/cyclophosphamide/low-dose total body irradiation (TBI) and allogeneic hematopoietic cell transplantation (HCT) for the stabilization or regression of disease manifestations of severe systemic sclerosis (SSc). SECONDARY OBJECTIVES: I. To determine whether stable allogeneic donor engraftment can ...

Phase

Fludarabine Busulfan and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

OBJECTIVES: - To assess the safety and feasibility of reduced-intensity preparative regimen comprising fludarabine, busulfan, and alemtuzumab followed by allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies or other diseases. - To assess the rate of donor engraftment in patients treated with this regimen. OUTLINE: This is a ...

Phase

Lenalidomide Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II Stage III or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

OBJECTIVES: Primary - To determine the maximum tolerated dose of lenalidomide when given in combination with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone in patients with newly diagnosed stage II-IV diffuse large cell or grade 3 follicular B-cell lymphoma. (Phase I) - To assess the efficacy of this regimen, in ...

Phase

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

The primary objective of this study is to evaluate the toxicity (as measured as 100 day survival) after hematopoietic stem cell transplant from an unrelated donor with a novel preparative regimen of Fludarabine, Busulfan, Anti-Thymocyte Globulin, and Total Body Irradiation for pediatric patients with leukemia. The secondary objectives are to ...

Phase